Business Context and Reporting Period
This Form 8-K Current Report was filed by Dianthus Therapeutics, Inc. on January 22, 2024. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement for a private placement expected to close on January 24, 2024. The transaction involves the sale of:
- Common Stock: 14,500,500 shares at $12.00 per share.
- Pre-Funded Warrants: 4,666,332 warrants to purchase common stock at $11.999 per warrant.
- Total Aggregate Purchase Price: Approximately $230 million.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this document focuses solely on the capital raise transaction.
Material Changes and Transaction Structure
The primary material change is the execution of the private placement to raise capital. Key structural terms include:
- Beneficial Ownership Limit: Holders of Pre-Funded Warrants are restricted from exercising if it would result in beneficial ownership exceeding 9.99% of outstanding shares immediately post-exercise. This limit may be increased to 19.99% with 61 days' prior notice.
- Registration Rights: The Company entered into a Registration Rights Agreement requiring the filing of a registration statement for the resale of securities no later than the second business day following the later of the 2023 Form 10-K filing or the effectiveness of the Form S-1. The Company must use commercially reasonable efforts to have the statement effective within 30 days.
- Placement Agents: Jefferies LLC, Evercore ISI, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC, and Raymond James & Associates, Inc. were engaged as placement agents.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers. The securities are being sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. The Company has agreed to indemnify Purchasers under the registration statement and pay associated fees and expenses, excluding legal fees of selling holders and underwriting discounts.
Investor Verification Checklist
- Verify the closing date of the private placement (expected January 24, 2024) and the actual receipt of the approximately $230 million proceeds.
- Confirm the filing and effectiveness of the registration statement for the resale of the Common Shares and Pre-Funded Warrant Shares as required by the Registration Rights Agreement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Pre-Funded Warrant (Exhibit 4.1) for specific covenants and conditions to closing.
- Monitor the Company's cash position post-closing to assess runway for clinical development, given the lack of revenue data in this filing.